<DOC>
	<DOCNO>NCT00365755</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill tumor cell . Giving combination chemotherapy surgery may make tumor small reduce amount normal tissue need remove . A bone marrow transplant , use bone marrow patient , may able replace blood-forming cell destroy chemotherapy . It yet know combination chemotherapy schedule effective , give surgery autologous bone marrow transplant , treat patient disseminate neuroblastoma . PURPOSE : This randomized phase III trial study two different chemotherapy schedule compare well work treat young patient undergo surgery autologous bone marrow transplant disseminate neuroblastoma .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Young Patients Who Are Undergoing Surgery Autologous Bone Marrow Transplant Disseminated Neuroblastoma</brief_title>
	<detailed_description>OBJECTIVES : - Compare response rate ( bone marrow primary tumor ) young patient disseminate neuroblastoma treat two different combination chemotherapy schedule comprise vincristine , cyclophosphamide , cisplatin , etoposide , carboplatin follow surgery autologous stem cell transplantation . - Compare event-free survival patient treat regimen . - Compare prognostic factor patient treat regimen . - Compare toxicity regimens patient . OUTLINE : This randomize , multicenter study . Patients randomize 1 2 treatment arm . - Arm I ( OPEC/OJEC ) : Patients receive OPEC combination chemotherapy comprise vincristine IV , cyclophosphamide IV , cisplatin IV continuously 24 hour , etoposide IV 4 hour day 1 course 1 . Patients receive OJEC combination chemotherapy comprise vincristine IV , cyclophosphamide IV , etoposide IV 4 hour , carboplatin IV 1 hour day 1 course 2 . OPEC OJEC regimens alternate patient receive 4 course OPEC 3 course OJEC 18 week absence disease progression unacceptable toxicity . - Arm II ( Rapid COJEC ) : Patients receive vincristine IV carboplatin IV 1 hour day 1 etoposide IV 4 hour day 1 2 ( regimen 1 ) . Ten day later , patient receive vincristine IV follow cisplatin IV continuously 24 hour day 1 ( regimen 2 ) . Ten day later , patient receive vincristine IV day 1 etoposide IV 4 hour cyclophosphamide IV day 1 2 ( regimen 3 ) . Treatment continue 10 week ( 10-day interval regimen order : regimen 2 , regimen 1 , regimen 2 , regimen 3 , regimen 2 ) absence disease progression unacceptable toxicity . Patients achieve bone marrow complete remission undergo surgery . Patients achieve bone marrow partial remission less remove study . After surgery , patient receive cyclophosphamide IV day -7 undergo bone marrow harvest day 1 . Patients receive high-dose melphalan IV day 1 . Autologous bone marrow cell reinfused day 3 . After completion study treatment , patient follow periodically . PROJECTED ACCRUAL : A total 190 patient accrue study .</detailed_description>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm disseminate neuroblastoma No local regional neuroblastoma No disseminate disease demonstrate metaiodobenzylguanidine ( MIBG ) scan Needle biopsy primary tumor require Fine needle aspiration adequate PATIENT CHARACTERISTICS : Not specify PRIOR CONCURRENT THERAPY : No prior chemotherapy No prior therapy</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>disseminate neuroblastoma</keyword>
</DOC>